We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Irras Ab | LSE:0GDW | London | Ordinary Share | SE0008321202 | IRRAS ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 29.038 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
STOCKHOLM, Nov 7, 2018 /PRNewswire/ -- On Thursday November 8, at 04.00 p.m. CET IRRAS will host a conference call and an online presentation of its Q3 2018 interim report (which is published the same day at 08.00 a.m. CET).
The dial-in numbers for the conference call are:
Sweden: +46 8 566 426 91
Rest of the world: +44 20 3008 9810
The presentation will also be webcast and can be accessed from the following web address:https://financialhearings.com/event/10811
Hosts: President CEO Kleanthis G. Xanthopoulos, Ph.D. and CFO and Deputy CEO Fredrik Alpsten
Investor and Media Contact:
Fredrik Alpsten, CFO and Deputy CEO+46 706 67 31 06
fredrik.alpsten@irras.com
About IRRAS
IRRAS AB (Nasdaq First North Premier: IRRAS) is a publicly-traded, commercial-stage medical technology company focused on developing and commercializing innovative solutions for brain surgery. The company's initial product, IRRAflow®, addresses the complications associated with the current methods of managing intracranial fluid by using a dual lumen catheter that combines active irrigation with ongoing fluid drainage. IRRAflow received FDA clearance in July 2018.
Regularly during treatment, the IRRAflow catheter is automatically flushed to prevent common catheter occlusions from forming. Because IRRAflow is a completely closed system, it is designed to reduce the documented infection risk of these procedures. Additionally, IRRAflow incorporates ICP monitoring and uses a proprietary software to regulate treatment based on desired pressure levels.
With its unique product portfolio, protected by property patents and patent applications, IRRAS is well positioned to establish a leadership position in the medical device market. IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/irras/r/irras-ab---q3-report-2018---invitation-to-conference-call-and-webcast,c2666556
The following files are available for download:
http://mb.cision.com/Main/16550/2666556/940708.pdf | Press release (PDF) |
View original content:http://www.prnewswire.com/news-releases/irras-ab--q3-report-2018--invitation-to-conference-call-and-webcast-300745674.html
SOURCE IRRAS
Copyright 2018 PR Newswire
1 Year Irras Ab Chart |
1 Month Irras Ab Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
